Download PDF
CC BY-NC-ND 4.0 · Klin Monbl Augenheilkd 2024; 241(04): 432-434
DOI: 10.1055/a-2244-6657
Der interessante Fall

The Importance of QuantiFERON Gold Plus Test for the Diagnosis of Presumed Ocular Tuberculosis

Die Bedeutung des QuantiFERON Gold Plus-Tests für die Diagnose der vermuteten Augentuberkulose
Francesca Bruzzone
1   Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, Switzerland
,
Margherita Plebani
2   Pediatric Infectious Diseases and Vaccinology Unit, Department Women-Mother-Child, Lausanne University Hospital, CHUV, Lausanne, Switzerland
,
Aikaterini Koryllou
3   Unit of Pediatric Rheumatology, Immunology and Allergology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
,
Matthieu Perreau
4   Division of Immunology and Allergy, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland
,
Yan Guex-Crosier 
1   Ophthalmology, Jules-Gonin Eye Hospital, University of Lausanne, Switzerland
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Background

In 2021, the World Health Organization (WHO) estimated 10.6 million new cases of active tuberculosis (TB) [1]. A TB infection results from the inhalation of small droplets contaminated with Mycobacterium tuberculosis (Mtb). Within 4 to 12 weeks after inhalation, a local tissue response and, in some cases, a hematogenous dissemination of Mtb occurs. Although the lung is the primary site of infection and pulmonary TB can be easily diagnosed by chest X-ray, extrapulmonary manifestations are not uncommon. After primary infection, patients may completely clear the Mtb, develop TB disease, or enter a latent stage (latent tuberculosis infection, LTBI) [2]. Reactivation of TB may occur without systemic symptoms and in extrapulmonary localization. In LTBI and in some extrapulmonary reactivations, diagnosis relies on indirect methods that assess the presence of sensitized lymphocytes capable of releasing cytokines when stimulated by mycobacterial antigens [3].



Publication History

Received: 03 October 2023

Accepted: 20 November 2023

Article published online:
23 April 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 World Health Organization (WHO). Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Accessed January 18, 2024 at: https://www.who.int/publications/i/item/9789240037021
    Google Scholar
  • 2 Ducommun MA, Eperon S, Khonkarly MB. et al. Long-term close follow-up of chorioretinal lesions in presumed ocular tuberculosis. Eur J Ophthalmol 2012; 22: 195-202
    CrossrefPubMedGoogle Scholar
  • 3 Villiger PM, Zellweger JP, Möller B. Novel screening tools for latent tuberculosis: time to leave an old friend?. Curr Opin Rheumatol 2009; 21: 238-243
    CrossrefPubMedGoogle Scholar
  • 4 Gupta V, Gupta A, Rao NA. Intraocular tuberculosis: an update. Surv Ophthalmol 2007; 52: 561-587
    CrossrefPubMedGoogle Scholar
  • 5 Standardization of Uveitis Nomenclature (SUN) Working Group. Classification criteria for sarcoidosis-associated uveitis. Am J Ophthalmol 2021; 228: 142-151
    CrossrefPubMedGoogle Scholar
  • 6 Jones BE, Jampol LM, Yannuzzi LA. et al. Relentless placoid chorioretinitis: A new entity or an unusual variant of serpiginous chorioretinitis?. Arch Ophthalmol 2000; 118: 931-938
    PubMedGoogle Scholar
  • 7 Pai M, Behr M. Latent Mycobacterium tuberculosis infection and interferon-gamma release assays. Microbiol Spectr 2016; 4 DOI: 10.1128/microbiolspec.TBTB2-0023-2016.
    CrossrefPubMedGoogle Scholar
  • 8 Pai M, Riley LW, Colford jr. JM. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4: 761-776
    CrossrefPubMedGoogle Scholar
  • 9 Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part 1. Latent tuberculosis. Expert Rev Mol Diagn 2006; 6: 413-422
    CrossrefPubMedGoogle Scholar
  • 10 Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354
    CrossrefPubMedGoogle Scholar
  • 11 Carvalho AC, Pezzoli MC, El-Hamad I. et al. QuantiFERON-TB Gold test in the identification of latent tuberculosis infection in immigrants. J Infect 2007; 55: 164-168
    CrossrefPubMedGoogle Scholar
  • 12 Andersen P, Munk ME, Pollock JM. et al. Specific immune-based diagnosis of tuberculosis. Lancet 2000; 356: 1099-1104
    CrossrefPubMedGoogle Scholar
  • 13 Kweon OJ, Lim YK, Kim HR. et al. Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care Workers. J Clin Microbiol 2019; 57: e01347-19
    CrossrefPubMedGoogle Scholar
  • 14 Banaei N, Gaur RL, Pai M. Interferon gamma release assays for latent tuberculosis: what are the sources of variability?. J Clin Microbiol 2016; 54: 845-850
    CrossrefPubMedGoogle Scholar
  • 15 Qiagen. QuantiFERON-TB Gold (QFT) ELISA package insert. Germantown, MD: Qiagen; 2016
    Google Scholar
  • 16 SD Biosensor. Standard E TB-Feron ELISA package insert. Gyeonggi-do, Republic of Korea: SD Biosensor; 2019
    Google Scholar
  • 17 Yamasue M, Komiya K, Usagawa Y. et al. Factors associated with false negative interferon-γ release assay results in patients with tuberculosis: A systematic review with meta-analysis. Sci Rep 2020; 10: 1607
    CrossrefPubMedGoogle Scholar